Quarterly Revenue of $123 Million, an Increase of 43% YoY Gross Profit of $57 Million, an Increase of 68% YoY Gross Margin of 46%, an Increase of 676bps YoY, 149bps QoQ Over Prior Adjusted Gross Margin1 Adjusted EBITDA of $17 Million, an Increase of 3
Lead AMHR2 agonist compound demonstrates high specific activity in biological assays and desired pharmacokinetic profile in preclinical animal studies NEW YORK--(BUSINESS WIRE)--Celmatix Inc. a biotechnology company focused on ovarian biology, today anno
WINNIPEG, Manitoba--(BUSINESS WIRE)--Ag Growth International Inc. (TSX: AFN) ("AGI" or the "Company") is pleased to announce the voting results from its annual meeting of shareholders held on May 13, 2022. A total of 9,971,406 common shares, representing
CHAPEL HILL, N.C., TORONTO & LONDON--(BUSINESS WIRE)--#HEOR--AESARA (www.aesara.com) is pleased to announce their attendance and poster presentations this ISPOR 2022 held in Washington, D.C. from May 16 – 18, 2022. A total of six posters will be present
Appoints: Commercial Managing Director, Europe; and Chief Growth Officer BURLINGTON, Ontario--(BUSINESS WIRE)--Anaergia Inc. (“Anaergia” or the “Company”) (TSX: ANRG) announces the promotion of two members of its leadership team to fill newly cre
LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its 2022 A
MISSISSAUGA, Ontario--(BUSINESS WIRE)--$MDX #SkinCancer--MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX) has announced that, in connection with the Private Placement ( the “Financing”) originally announced in its press release dated Ma
Introduces Co-Digestion at Wastewater Treatment Plant in Canada BURLINGTON, Ontario--(BUSINESS WIRE)--Anaergia Inc. (“Anaergia” or the “Company”) (TSX: ANRG) announced that it signed a design-build agreement with the Town of Petawawa, Ontario. Un
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ultivue, Inc., an industry leader in multiplexing assays and analytics solutions for tissue biomarker studies, announced today multiple collaborations for AI-powered spatial phenomics solutions for translational research
BURLINGTON, Ontario--(BUSINESS WIRE)--Rapid Dose Therapeutics Corp. (“RDT”), (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, provides the following update regarding the signing of a number of
Our partner BioTalent Canada has launched the Building Workplace Resiliency resources for its I.D.E.A.L. Biosciences Employer Recognition Program. This program served as a guide for employers seeking to submit fall program applications.
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.